Compare companies
Minerva Neurosciences, Inc. | Gilead Sciences | Amgen | ||||
---|---|---|---|---|---|---|
Capitalization | ||||||
Price | 1.865 | 107.89 | 306.86 | |||
Price priv. | ||||||
Number of shares, million | 6.51 | 1258 | 538 | |||
Capitalization, billion | 0.0608 | 94.55 | 140.05 | |||
EBITDA, billion | -0.0231 | 7.61 | 7.9 | |||
EV, billion | 0.0855 | 119.11 | 206.55 | |||
Profit and loss report | ||||||
Net profit, billion | -0.03 | 5.67 | 6.72 | |||
Revenue, billion | 0.003 | 27.12 | 28.19 | |||
EPS | -4.61 | 4.5 | 12.49 | |||
Balance | ||||||
Assets, billion | 0.0569 | 62.13 | 97.15 | |||
Debt, billion | 0.082 | 24.99 | 64.61 | |||
Balance cost, billion | -0.0285 | 22.75 | 6.23 | |||
Cash, billion | 0.041 | 6.09 | 10.94 | |||
Coefficients | ||||||
Dividend yield, % | 0 | 3.69 | 2.92 | |||
Dividend | 0 | 3.87 | 9.13 | |||
Dividend yield priv., % | 0 | 0 | 0 | |||
Dividend priv. | 0 | 0 | 0 | |||
Dividends/profit, % | 0 | 67.24 | 67.83 | |||
P/S | 16.17 | 3.7 | 5.42 | |||
P/BV | -1.56 | 4.41 | 24.53 | |||
P/E | 0 | 17.69 | 22.76 | |||
Ev/Ebitda | -3.7 | 15.66 | 26.16 | |||
Debt/Ebitda | -3.55 | 3.29 | 8.18 | |||
Efficiency | ||||||
ROE | 105.44 | 24.9 | 107.78 | |||
ROA | -52.73 | 9.12 | 6.91 | |||
ROIC | 0 | 11.06 | 17 | |||
Ebitda margin | -768.4 | 28.05 | 28.01 | |||
Net margin | -1630.55 | 20.89 | 23.83 | |||
Momentum | ||||||
1 week, price changes | +7.8 % | +0.3535 % | -2.82 % | |||
1 month, price changes | +4.19 % | -2.83 % | -0.9234 % | |||
3 months, price changes | -19.96 % | +14.84 % | +16.02 % | |||
6 months, price changes | -30.93 % | +29.93 % | -3.84 % | |||
1 year, price changes | -27.71 % | +47.77 % | +7.18 % | |||
3 years, price changes | -70.07 % | +81.82 % | +31.59 % | |||
5 years, price changes | -78.41 % | +80.42 % | +33.46 % | |||
10 years, price changes | +24.66 % | +101.52 % |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription